Login

5-(N,N-Hexamethylene)-amiloride

CAT:
804-HY-128067-02
Size:
10 mM / 1 mL
Price:
Ask
For price, please contact [email protected]
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
5-(N,N-Hexamethylene)-amiloride - image 1

5-(N,N-Hexamethylene)-amiloride

  • Product Name Alternative: Hexamethylene amiloride; HMA
  • CAS Number: 1428-95-1
  • UNSPSC Description: 5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na+/H+ exchanger inhibitor, which decreases the intracellular pH (pHi) and induces apoptosis in leukemic cells. 5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) is also an inhibitor of the HIV-1 Vpu virus ion channel and inhibits mouse hepatitis virus (MHV) replication and human coronavirus 229E (HCoV229E) replication in cultured L929 cells with EC50s of 3.91 μM and 1.34 μM, respectively[1][2].
  • Target Antigen: Apoptosis; HIV; Sodium Channel
  • Type: Reference compound
  • Related Pathways: Anti-infection;Apoptosis;Membrane Transporter/Ion Channel
  • Field of Research: Cancer; Infection
  • Assay Protocol: https://www.medchemexpress.com/5-n-n-hexamethylene-amiloride.html
  • Purity: 98.47
  • Solubility: DMSO : 100 mg/mL (ultrasonic)
  • Smiles: O=C(C1=NC(Cl)=C(N2CCCCCC2)N=C1N)NC(N)=N
  • Molecular Weight: 311.77
  • References & Citations: [1]Rich IN, et al. Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood. 2000 Feb 15;95(4):1427-34.|[2]Wilson L, et al. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology. 2006 Sep 30;353(2):294-306. Epub 2006 Jul 3.|[3]Buckley BJ, et al. Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride. Bioorg Med Chem. 2021 May 1;37:116116.
  • Shipping Conditions: Room Temperature
  • Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information: No Development Reported